Can men 'Comeback' from prostate cancer treatment? trial tests hormone recovery
NCT ID NCT06463457
Summary
This study is testing a two-drug combination (relugolix and darolutamide) for men with hormone-sensitive prostate cancer. The main goal is to see if men's testosterone levels return to normal within 18 months after finishing the two-year treatment. Researchers will also closely monitor the safety of using these two drugs together in 33 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.